If subject is currently receiving a tricyclic antidepressant anticonvulsant and/or Class I antiarrhythmic e.g. amitriptyline mexiletine phenytoin gabapentin or carbamazepine for treatment of pain or any other condition subject must be willing and able to maintain stable doses of these agents within 4 weeks prior to randomization and throughout the study i.e. doses can not be increased or decreased during this period 